Epicardial adipose tissue is associated with increased systolic pulmonary artery pressure in patients with chronic obstructive pulmonary disease
暂无分享,去创建一个
E. Kalaycıoğlu | M. Çetin | G. Çinier | T. Gökdeniz | T. Kırış | I. Durmuş | Ali Gökhan Özyıldız | A. G. Özyıldız
[1] G. Hindricks,et al. Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. , 2019, Atherosclerosis.
[2] Li Sun,et al. Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea , 2019, Journal of the American Heart Association.
[3] Shing‐Jong Lin,et al. Association between echocardiographic epicardial fat thickness and circulating endothelial progenitor cell level in patients with stable angina pectoris , 2017, Clinical cardiology.
[4] P. Paré,et al. Increased Epicardial Adipose Tissue Is Associated with the Airway Dominant Phenotype of Chronic Obstructive Pulmonary Disease , 2016, PloS one.
[5] B. Lipworth,et al. The role of pulmonary arterial stiffness in COPD , 2015, Respiratory medicine.
[6] Gianluca Iacobellis,et al. Local and systemic effects of the multifaceted epicardial adipose tissue depot , 2015, Nature Reviews Endocrinology.
[7] J. Wells,et al. Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD , 2013, International Journal of COPD.
[8] B. Celli,et al. Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease , 2013, PloS one.
[9] D. Moertl,et al. Pulmonary artery pulse wave velocity in idiopathic pulmonary arterial hypertension. , 2013, The Canadian journal of cardiology.
[10] Khaled Z. Abd-Elmoniem,et al. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial , 2013, Trials.
[11] J. Loscalzo,et al. Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension , 2012, Circulation.
[12] W. Qin,et al. Assessment of the right ventricular function in patients with chronic obstructive pulmonary disease using MRI , 2011, Acta radiologica.
[13] S. Mueller,et al. Xanthine Oxidase Inhibition Attenuates Endothelial Dysfunction Caused by Chronic Intermittent Hypoxia in Rats , 2011, Respiration.
[14] Samir R. Thadani,et al. Epicardial fat volume in patients with left ventricular systolic dysfunction. , 2011, The American journal of cardiology.
[15] C. Lang,et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[16] N. Voelkel,et al. COPD/emphysema: The vascular story , 2011, Pulmonary circulation.
[17] H. Willens,et al. Echocardiographic epicardial fat: a review of research and clinical applications. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[18] R. Naeije,et al. Pulmonary hypertension in COPD , 2008, European Respiratory Journal.
[19] Mathias Prokop,et al. Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. , 2008, The American journal of cardiology.
[20] Crystal Kantores,et al. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[21] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[22] H. Sacks,et al. Human epicardial adipose tissue: a review. , 2007, American heart journal.
[23] R. Tkacova,et al. Systemic inflammation in patients with COPD and pulmonary hypertension. , 2006, Chest.
[24] B. Housset,et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. , 2006, Proceedings of the American Thoracic Society.
[25] J. Marcus,et al. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. , 2005, Chest.
[26] J. Gardin,et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[27] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[28] W. Haynes,et al. Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. , 2004, The American journal of cardiology.
[29] K. Shirato,et al. Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways , 2003, European Respiratory Journal.
[30] T. Veel,et al. Allopurinol inhibits hypoxic pulmonary vasoconstriction. Role of toxic oxygen metabolites , 1990, Acta anaesthesiologica Scandinavica.
[31] A. Ducoloné,et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. , 1981, Thorax.